Tokyo, Japan and Cambridge, UK, 9 August 2024 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the second...
Tokyo, Japan and Cambridge, UK, 9 July 2024 - Nxera Pharma Co. Ltd (“Nxera”; TSE 4565) will announce its earnings results and present operational highlights for the 6 months ended 30 June 2024 on...
Tokyo, Japan and Cambridge, UK, 27 June 2024 - Nxera Pharma Co. Ltd (“Nxera”; TSE 4565), announces that it has reached an important R&D milestone under its multi-target discovery collaboration...
Tokyo, Japan and Cambridge, UK, 18 June 2024 – Nxera Pharma (“Nxera” or “the Company”; TSE 4565), today announces the publication of its Annual Report and its Environment, Social & Governance...
Tokyo, Japan and Cambridge, UK, 30 May 2024 “ Nxera Pharma (the Company or Nxera; TSE: 4565) today announced that it expects to receive $4.6 million in milestone payments from Centessa...
Expansion of existing partnership will utilize novel insights into causal biology within auto-immune disorders to identify novel targets for drug discovery Tokyo, Japan, Oxford and Cambridge,...
Compugen, Nxera disclose milestone payments; Insmed aims for $650M offering
Tokyo, Japan and Cambridge, UK, 9 May 2024 “ Nxera Pharma (the Company or Nxera; TSE: 4565) notes that its partner Neurocrine Biosciences Inc. (Neurocrine; Nasdaq: NBIX), a leading...
Freeline Presents Positive New Data from Phase 1/2 Trial of FLT201, Its Novel Gene Therapy Candidate for Gaucher Disease, in Late-Breaking Oral Presentatio
Tokyo, Japan and Cambridge, UK, 17 April 2024 “ Nxera Pharma Co. Ltd (Nxera or the Company; TSE 4565) “ formerly known as Sosei Group or Sosei Heptares “ announces that it has decided to issue new...